# Ferroptosis-inducing payloads and antibody-directed carriers

Source: https://onco.cc/terms/ferroptosis-conjugate-payloads/  
OnCo record `ferroptosis-conjugate-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ferroptosis is cell death caused by damage to fatty molecules in cell membranes. Antibody-directed carriers are being studied to deliver drugs that trigger it in tumors.

## Summary

A primary study linked an FGFR4 antibody to the ferroptosis inducer sulfasalazine through a cleavable linker and reported target-dependent activity in liver cancer models. A separate study used an anti-PD-L1 antibody linked to a nanogel encapsulating imidazole ketone erastin, or IKE, with ferroptosis and tumor suppression in experimental models. The former is a directly conjugated small-molecule payload; the latter is an antibody-directed nanocarrier. Both are preclinical evidence and should retain their different delivery formats.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: ferroptosis payloads; sulfasalazine payload; IKE antibody nanogel conjugate

## Notes

- These studies concern sulfasalazine and IKE. They do not establish that every inhibitor of the ferroptosis-defense protein GPX4 can be made into a conventional antibody payload.

## Sources

- FGFR4 conjugate carrying sulfasalazine (2025): https://doi.org/10.1016/j.isci.2025.113718
- Antibody nanogel delivery of a ferroptosis inducer (2024): https://doi.org/10.1016/j.chembiol.2024.10.014

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)

---
JSON: https://onco.cc/api/v1/entities/ferroptosis-conjugate-payloads.json